Skip to main content

Table 2 Treatment-related toxicity.

From: Continuous 5-fluorouracil infusion plus long acting octreotide in advanced well-differentiated neuroendocrine carcinomas. A phase II trial of the Piemonte Oncology Network

Higher grade WHO toxicity

N = 29

No. (%)

N = 29

No. (%)

N = 29

No. (%)

 

1

2

3

Anemia

--

2 (6.9)

--

Thrombocytopenia

1 (3.4)

--

--

Neutropenia

2 (6.9)

2 (6.9)

--

Asthenia

9 (31.0)

2 (6.9)

--

Nausea-vomiting

7 (24.1)

1 (3.4)

--

Diarrhea

16 (55.1)

2 (6.9)

1(3.4)

Hand-foot syndrome

4 (13.8)

4 (13.8)

2 (6.9)

Mucositis

4 (13.8)

2 (6.9)

1 (3.4)